EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Performance of the accelerated assessment of the European Medicines Agency

Vittorio Del Grosso, Martina Perini, Giorgio Casilli, Enrico Costa, Valentina Boscaro, Gianluca Miglio iD, Armando A Genazzani

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16385 ↗

At a glance

Journal article in British Journal of Clinical Pharmacology, 2025. Written by Vittorio Del Grosso and 6 co-authors. Institution: Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy. Major MEDLINE topics: Technology Assessment, Biomedical, Drug Approval. Cited 6 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0). Funded by: Italian Ministry of Education to A.A.G., Italian Ministry of Health to A.A.G..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

In Europe, the European Medicines Agency (EMA) has an accelerated pathway to prioritize approval of medicines. Approved drugs are then assessed by Health Technology Assessment (HTA) bodies before being made available to patients. The aim of the study was to evaluate the characteristics of the drugs admitted to the EMA accelerated assessment (AA) and scrutinize the downstream HTA procedures regarding these medicines and the final assessment regarding added therapeutic value (ATV).

Methods

Regulatory publicly available documents were scrutinized for all medicines authorized by the EMA between 2019 and 2021 to create a regulatory database. A second database was created by extracting data of the medicines that had requested the EMA accelerated pathway from three national HTA bodies (AIFA, HAS and G‐BA).

Results

Standard assessments by the EMA had a median of 364 days while AAs were significantly shorter (189 days). Only 12 out of 164 authorized medicines were assessed in this manner. Small chemical entities had a significantly lower chance of being assessed under the AA, while biological and PRIME scheme medicines had a higher chance; AA had a higher chance of leading to authorizations under exceptional circumstances. These 12 products were assessed more quickly compared to other products by HTA bodies, although this did not always lead to decisions of major ATV over alternatives.

Conclusions

A minority of medicinal products are assessed under the accelerated pathway. HTA bodies also assess these products more quickly, but do not always perceive an important clinical advantage over alternatives.

Subjects

MeSH terms (MEDLINE)

Technology Assessment, BiomedicalDrug ApprovalHumansEuropeDatabases, Factual

Author keywords

Agenzia Italiana del Farmaco (AIFA)Der Gemeinsame Bundesausschuss (G‐BA)European Medicines AgencyHaute Autorité de Santé (HAS)accelerated assessmentdrug regulation

Authors and institutions

  • Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy.
  • More Than Access (MTA) Srl SB, Milan, Italy.
  • Agenzia Italiana del Farmaco (AIFA), Rome, Italy.
  • WHO Collaborating Centre for Pharmaceutical Policy and Regulations, Utrecht University, Utrecht, The Netherlands.
  • Department of Drug Science and Technology, University of Turin, Turin, Italy.

ORCID profiles: Gianluca Miglio

Funding

  • Italian Ministry of Education to A.A.G.
  • Italian Ministry of Health to A.A.G.

Cite

APA

Del Grosso, V., Perini, M., Casilli, G., Costa, E., Boscaro, V., Miglio, G., & Genazzani, A. A. (2025). Performance of the accelerated assessment of the European Medicines Agency. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16385

Vancouver

Del Grosso V, Perini M, Casilli G, Costa E, Boscaro V, Miglio G, et al. Performance of the accelerated assessment of the European Medicines Agency. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16385

BibTeX
@article{DelGrosso2025,
  author = {Del Grosso, Vittorio and Perini, Martina and Casilli, Giorgio and Costa, Enrico and Boscaro, Valentina and Miglio, Gianluca and Genazzani, Armando A},
  title = {Performance of the accelerated assessment of the European Medicines Agency},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16385}
}
Start for free →